Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The three sites in Anagni, Italy, Brussels in Belgium, and Bloomington, Indiana, in the US will change hands “as soon as possible after the merger,” said Novo Nordisk, which has pledged to ...

The letter indicates that Novo Nordisk already has 55% of the market ... sites covered by the deal is located in the US – at Bloomington, Indiana – while the other two are at Anagni in Italy ...

The analyst highlights that Lilly’s drugs, Mounjaro and Zepbound, will likely keep gaining U.S. market share from Novo ...

(Bloomberg) -- Novo Nordisk A/S can advance with its acquisition ... The three factories, located in Anagni, Italy, Brussels and Bloomington, Indiana, focus on the stages of drug production ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer ...

Novo Nordisk (NVO) closed the most recent trading day at $69.30, moving -1.23% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 1.97%.

April 14 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its authorized supply chain ...